title: Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality.
abstract: OBJECTIVE
  The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy.
  
  
  METHODS
  Thirty-five patients with radicular pain and diagnosed as L4, L5 or S1 radiculopathy were treated with oral gabapentin from a total of 300 mg per day once up to a total of 1800 mg per day divided in 3 doses for eight-week trial period. Quality of life, functional disability and psychological mood of the patients were assessed using the Nottingham Healthy Profile (NHP), Oswestry Low Back Pain Disability Questionnaire (ODQ) and Beck Depression Inventory (BDI).
  
  
  RESULTS
  Of the patients (n = 35), 25 were females and 10 were males (mean age: 41.8 +/- 10.4, range: 24-60 years); mean radiculopathy duration was 16.4 +/- 14.2 months (range: 3-48 months). The pain intensity at rest, quality of life, functional disability and depression scores were determined significantly improved after treatment and 4 months compared to baseline scores (p < 0.001). 1.5 points compared to baseline for at pain rest and 15 points improvement on the ODQ were obtained.
  
  
  CONCLUSIONS
  Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic radiculopathy.
authors.affiliation: Department of Physical Medicine and Rehabilitation, School of Medicine, Ataturk University, Erzurum, Turkey. kadiryildirim88@hotmail.com
authors.forename: Kadir
authors.initials: K
authors.lastname: Yildirim
authors.forename: Orhan
authors.initials: O
authors.lastname: Deniz
authors.forename: Gurhan
authors.initials: G
authors.lastname: Gureser
authors.forename: Saliha
authors.initials: S
authors.lastname: Karatay
authors.forename: Mahir
authors.initials: M
authors.lastname: Ugur
authors.forename: Akin
authors.initials: A
authors.lastname: Erdal
authors.forename: Kazim
authors.initials: K
authors.lastname: Senel
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000209:etiology; D004185:Disability Evaluation; D005260:Female; D000077206:Gabapentin; D006801:Humans; D017116:Low Back Pain / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D011788:Quality of Life / Q000523:psychology*; D011843:Radiculopathy / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin